|
|
| Topiramate in a Nutshell |
| |
| |
Markets |
| |
- Topiramate is an orally administered drug marketed under the brand name of Topamax
- 2.7 million patients using a range of therapeutic options
- Total hospital costs in 2005 for epilepsy and convulsion patients was nearly $1.8 billion
|
| |
Product Advantages |
| |
- Physicians prefer to use the same therapeutic agent utilized to treat patients on a chronic, prophylactic basis
- Current formulation of Topamax is not optimal for acute use: patients may be unable to take oral medications and acute use is not currently approved for Topamax
- We believe that Captisol-Enabled Topiramate IV will provide for faster onset of drug while providing administration to a wider audience
|
| |
Development Status |
| |
- We are developing an IV formulation of topiramate in conjunction with the University of Minnesota to be used for the treatment of epilepsy
- Pre-IND meeting with the FDA held in May 2008
|
| Updated: May 29, 2008 | |
